Meeting slides
Suggested Readings

Heart disease and stroke statistics-2020 update: a report from the American Heart Association.

Virani et al. Circulation. 2020;141(9):e139-e596.

How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine.

McMurray et al. Circulation. 2021;143(9):875-877.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, et al. N Engl J Med. 2017;377(7):644-657.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

Wiviott SD, et al. N Engl J Med. 2019;380(4):347-357.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, et al. N Engl J Med. 2019;380(24):2295-2306.

Cardiovascular outcomes with ertugliflozin in type 2 diabetes.

Cannon CP, et al. N Engl J Med. 2020;383(15):1425-1435.

Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.

McGuire D, et al. JAMA Cardiol. 2021;6(2):148–158.

SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.

Zannad F, et al. Lancet. 2020;396:819-829.

Empagliflozin in heart failure with a preserved ejection fraction.

Anker et al. N Engl J Med. 2021;385(16):1451-1461.

Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.

Solomon et al. N Engl J Med. 2022;387(12):1089-1098.

Related activities
1.25 CME/CE

Making the Call in Heart Failure

Multidimensional Outcomes with SGLT2 Inhibitors

Faculty: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP; Javed Butler, MD, MPH, MBA; Christopher P. Cannon, MD
Release: 11/18/2022
Expiration: 11/18/2023